Ovid Therapeutics Inc.
OVID
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complexā¦ read more
Healthcare
Biotechnology
6 years
USD
55
/100
Price
per share adjusted in USD$0.57
Price-3.11%
-$0.02
Market Cap
$40.263m
Small
Price/Earnings
-0.8x
-
3y Avg-
5y AvgReturns
Adjusted for dividendsDividends
Ex-Dividend: -0.00%
Yield$0.00
Dividend0.00%
Forward Dividend Growth
-
-
3y CAGR-
5y CAGRPayout
0.00%
-
Payout 3y-
Payout 5yYield
BenchmarkDividends
No items found.
Financials Overview
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$567.530k
-
1y CAGR-
3y CAGR-
5y CAGREarnings
-$29.747m
-
1y CAGR-
3y CAGR-
5y CAGREPS
-$0.43
-
1y CAGR-
3y CAGR-
5y CAGRBook Value
$88.903m
$118.093m
Assets$29.190m
Liabilities$16.362m
DebtDebt to Assets
13.9%
-0.2x
Debt to EBITDAFree Cash Flow
-$52.964m
-
1y CAGR-
3y CAGR-
5y CAGRFinancial Reports
Earnings and other important metricsNo items found.
Press Releases